Compare Sana Biotechnology Inc (SANA) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Sana Biotechnology Inc trades at $3.76 (market cap $1.13B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.15. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | SPUS | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $59.51 |
52-Week Low | $2.68 | $46.28 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
SPUS trades at $59.11, up 0.27% today, with a bullish technical signal supported by moving averages. The stock shows strong momentum indicators but an overbought RSI-6. Dividend payments of $0.03 are scheduled for mid-2026, indicating income focus. Recent news highlights the resilience of US dividend strategies amid market concentration.
The outlook remains positive given technical strength and dividend consistency, but overbought conditions near-term suggest caution. Risks include market volatility and reliance on dividend strategy performance. Analyst sentiment is supportive, with institutional interest in dividend-focused equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
